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Pilot Study for Subgroup Classification for Autism Spectrum Disorder Based  
on Dysmorphology and Physical Measurements in Chinese Paediatric and  
Adolescent Population
Polly TY Wong, Virginia CN Wong
Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong SAR
Background: Autism	spectrum	disorder	(ASD)	is	defined	as	a	range	of	complex	neurodevelopmental	
disorder	affecting	 individuals	along	a	continuum	of	severity	 in	communication,	social	 interaction	
and	behaviour.	The	impact	of	ASD	significantly	varies	among	individuals,	and	the	cause	of	ASD	can	
originate	broadly	between	genetic	and	environmental	factors.	Previous	ASD	researches	indicate	that	
early	identification	combined	with	a	targeted	treatment	plan	involving	multidisciplinary	therapies	and	
behavioural	 interventions	can	bring	about	substantial	 improvement	to	the	development	of	autistic	
patients.	Currently	there	is	no	cure	for	ASD,	and	the	clinical	variability	and	uncertainty	of	the	disorder	still	
remains.	Hence,	the	search	to	unravel	heterogeneity	within	ASD	by	subgroup	classification	may	provide	
clinicians	with	a	better	understanding	of	ASD	and	allow	for	a	more	definitive	course	of	action.
Methods:	In	this	study,	a	norm	of	physical	measurements	including	height,	weight,	head	circumference,	
ear	 length,	outer	and	 inner	canthus,	 interpupillary	distance,	philtrum,	hand	and	foot	 length	were	
collected	from	658	normal	Chinese	children	aged	1	to	7	years.	The	norm	collected	was	compared	against	
80	Chinese	ASD	children	aged	1	to	12	years.	We	attempted	to	find	subgroups	within	ASD	subjects	based	
on	identifying	physical	abnormalities;	 individuals	were	classified	as	(non)dysmorphic	with	the	Autism	
Dysmorphology	Measure	(ADM)	Scoring	Algorithm	from	physical	examinations.
Results: Our	results	showed	that	there	was	a	significant	difference	(P<0.05)	between	age-matched	normal	
controls	and	ASD	group	in	measurements	for	head	circumference,	outer	and	inner	canthus,	philtrum	
length,	right	and	left	foot	length.	Within	the	80	ASD	patients,	39	were	defined	as	dysmorphic	(P=0.00).
Conclusion:	 This	 study	attempted	 to	 identify	 subgroups	within	ASD	patients	based	on	physical	
measurements	and	dysmorphology	examinations.	The	information	from	this	study	seeks	to	benefit	ASD	
community	by	identifying	the	possible	subtypes	of	ASD	in	Chinese	preschool	population,	and	to	seek	for	
a	more	definitive	diagnosis,	referral,	and	treatment	plan.
FP 1
10      Hong Kong Med J Vol 19 No 6 # Supplement 6 # December 2013
Promotion of Physical Activity and Fitness in the Parki-Fit & Walk Program  
Addressing the Non-motor Symptom ‘Fatigue’ for Idiopathic Parkinson’s Disease
CM Kwok1, HT Lui2, LF Hui2, KY Wong1
1 Physiotherapy Department, Integrated Rehabilitation Services, Tseung Kwan O Hospital, Hong Kong SAR
2 Division of Neurology, Department of Medicine, Tseung Kwan O Hospital, Hong Kong SAR
Introduction: Idiopathic	Parkinson’s	disease	(iPD)	is	often	complicated	with	various	motor	and	non-motor	
symptoms,	which	has	great	impact	in	daily	functions,	fitness,	and	quality	of	life	(QoL)	wellbeing.	Fatigue	
is	one	of	the	common	irritating	non-motor	symptoms.	It	often	appears	as	an	obstacle	to	daily	physical	
exercise	adherence.	However,	 limited	clinical	research	addressed	its	 impacts	during	the	process	of	
rehabilitation.	
Objectives:	(1)	To	evaluate	the	impact	of	non-motor	symptom,	fatigue,	on	health	fitness,	QoL	and	amount	
of	physical	activity	after	participating	the	Parki-Fit	&	Walk	Program;	and	(2)	to	determine	the	predicting	
factors	contributing	to	the	change	of	endurance	capacity	through	physical	exercise	in	daily	living.	
Methods: After	iPD	patients	received	pharmacological	control	from	Neurology	Clinic	and	Integrated	PD	
Service,	indicated	patients	will	be	recruited	in	the	Parki-fit	&	Walk	Program	for	6	months.	It	was	designed	
for	multifaceted	behavioural	change	with	various	strategies	to	achieve	better	QoL	and	health	fitness,	via	
promoting	active	lifestyle	towards	moderate	physical	activity	level.	The	amount	of	physical	activity	was	
measured	by	a	standardised	7-day	recall	questionnaire	(Physical	Activity	Recall	Questionnaire	[PARQ]).	
Details	of	program	workflow	include	20	iPD	patients	in	the	‘fatigue’	group	(FG)	and	26	in	the	‘non-fatigue’	
group	(NFG).	They	were	identified	by	employing	the	9-item	Fatigue	Severity	Scale	(FSS),	which	reflected	
physical	and	mental	fatigue.	The	individual	score	of	the	mean	of	the	numerical	responses	was	calculated;	
a	cut-off	of	4	was	used	to	select	fatigued	from	non-fatigued.
Results:	The	NFG	increased	by	70%	and	the	FG	 increased	by	49.6%	in	 total	energy	expenditure	of	
moderate	physical	activities	(P=0.001;	repeated	measured	ANOVA)	after	intervention.	They	all	achieved	
the	recommended	moderate	physical	exercise	level.	Both	groups	obtained	obvious	health	fitness	gain.	
Motor	control	(UPDRS	motor	score)	improved	by	33%	in	NFG	and	6.4%	in	FG;	walking	endurance	(6-minute	
walk	distance)	improved	by	32.5%	in	NFG	and	0.6%	in	FG;	comfort	gait	speed	improved	by	33.8%	in	NFG	
and	4.3%	in	FG;	QoL	wellbeing	(Motor	score	in	Parkinson’s	disease	39	Questionnaire)	improved	by	67.4%	
in	NFG	and	6.4%	in	FG	(P=0.001;	repeated	measured	ANOVA).	The	linear	stepwise	multivariate	regression	
analysis	showed	the	change	of	walking	endurance	was	associated	with	change	of	gait	speed	and	change	
of	moderate	level	physical	exercises	(P=0.000).	This	model	predicted	61%	correctly	(R2=0.61).	The	change	
of	endurance	capacity	can	be	predicted	by	the	following	equation:	15.24	+	161.168	x	change	of	gait	speed	
+	0.05	x	change	of	moderate	level	physical	exercises	energy	expenditure	(n=46,	R2=0.61,	P=0.000).	
Conclusion:	The	study	suggested	that	early	multidisciplinary	team	approach	included	comprehensive	
evaluation,	customised	disease	management	and	training	program	like	the	Parki-fit	&	Walk	Program	will	
facilitate	holistic	care	in	iPD.	Determining	the	fatigue	level	may	facilitate	specialised	education,	exercise	
dosage	prescription,	and	program	adherence.	Further	researches	are	recommended	to	study	its	long-
term	effect	on	health	care	outcomes.
FP 2
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Cryptococcal Meningitis
Helen Yip, MC Kwan, WK Cheng, WY Lau, KF Ko
Department of Medicine and Geriatrics, Kwong Wah Hospital, Hong Kong SAR
We	report	a	case	of	cryptococcal	meningitis	in	an	immunocompetent	male	presented	with	fever	for	4	
months	despite	extensive	work-up.
	 A	63-year-old	man	Hong	Kong	resident	who	 is	a	 retired	shopkeeper	with	a	medical	history	of	
hypertension	and	 lumbar	spondylosis.	He	presented	to	our	Medical	Unit	 for	mental	dullness	with	
decreased	short-term	memory.	Before	current	admission,	 the	patient	was	admitted	to	Our	Lady	of	
Maryknoll	Hospital	 for	4-month	history	of	pyrexia	and	recently	diagnosed	pulmonary	cryptococcal	
infection	confirmed	with	 lung	biopsy	being	put	on	4	days	of	 fluconazole	 therapy	prior	 to	current	
admission.
	 On	examination,	the	patient	was	afebrile	with	a	Glasgow	Coma	Scale	score	of	E4M6V4.	Neck	rigidity	
was	negative.	Limb	muscle	power	was	equal	and	symmetrical.	Plantars	were	bilaterally	flexor.	Laboratory	
investigations	revealed	raised	total	leukocyte	count	(white	cell	count	[WCC],	15	x	109/L).	Blood	for	renal	
function	tests	and	liver	function	tests	were	normal.	Cerebrospinal	fluid	(CSF)	examination	revealed	
WBC	168/cm3	with	predominantly	lymphocytes	67%,	with	protein	of	7.03	g/L	and	glucose	of	0.9	mmol/L	
(corresponding	blood	glucose	was	6.0	mmol/L).	
	 There	were	no	microorganisms	on	Gram	and	Ziehl-Neelsen	(Z-N)	stains.	India	ink	examination	was	
negative	with	a	negative	growth	on	bacterial	culture.	The	CSF	and	serum	cryptococcal	antigen	were	
positive,	with	a	titre	of	1:256	with	culture	yield	Cryptococcus neoformans.
	 A	computed	tomography	(CT)	scan	of	the	brain	showed	hypodensity	over	right	caudate	nucleus	and	Lt	
pontine	area.	Mini-Mental	State	Examination	(MMSE)	was	19	out	of	30	on	admission.	His	complement	and	
immunoglobulin	levels	were	within	normal	limits.	Anti-HIV	antibody	was	negative	in	two	blood	samples	3	
months	apart.
	 He	was	started	on	antifungal	pharmacotherapy	with	amphotericin	B	with	addition	of	flucytosine	
(5FC)	as	induction	therapy.	Subsequent	MMSE	was	26	out	of	30	after	3	weeks	of	antifungal	treatment.	
Fluconazole	was	followed	as	consolidation	and	maintenance	therapy.
	 Most	cases	of	cryptococcal	meningitis	occur	 in	 immunocompromised	patients	but	 it	has	been	
reported	in	HIV-negative	patients	caused	by	chemotherapy-related	immunosuppression,	history	of	organ	
transplantation,	haematological	malignancies,	concurrent	use	of	corticosteroid	therapy,	and	sarcoidosis.	
Occasionally,	no	obvious	underlying	cause	can	be	detected.	
	 Cryptococcal	meningitis	remains	a	devastating	disease	with	a	high	mortality.	An	important	predictor	
of	early	mortality	is	an	abnormal	mental	status	at	presentation	and	mortality	can	be	up	to	25%.	Other	
prognostic	factors	include	baseline	high-opening	pressure,	poor	WCC	response	in	CSF,	high	CSF	titres	of	
cryptococcal	antigen	>1024,	positive	blood	culture	and	CSF	India	ink/Gram	stain	positivity.
	 Our	patient	had	a	gradual	 improvement	 in	cognition	and	mobility	after	prompt	treatment.	Early	
diagnosis	and	management	is	essential	to	hasten	recovery	in	cryptococcal	meningitis.
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A Young Lady with Artery of Percheron Infarction and Patent Foramen Ovale
SH Li, TY Wai, MF Ip, KK Ma
Department of Medicine, North District Hospital, Hong Kong SAR
A	30-year-old	woman	attended	Neurology	Clinic	at	North	District	Hospital	in	March	2010	for	investigation	
of	diplopia.	She	complained	of	a	period	of	impaired	consciousness	followed	by	diplopia	in	2003	when	
she	was	in	Mainland	China.	She	reported	gradual	recovery	afterwards	though	residual	diplopia	remained.	
She	had	no	head	or	neck	injury.	She	enjoyed	good	past	health.	
	 Neurological	examination	showed	impaired	downward	gaze	(pursuit	and	saccade).	Other	parts	
of	examination	were	unremarkable.	She	did	not	have	any	limb	weakness	or	ataxia.	Her	cognitive	was	
unremarkable.	Computed	tomographic	non-contrast	brain	revealed	bilateral	 thalamic	and	anterior	
midbrain	old	infarcts	(Fig	1).	Electrocardiogram	and	chest	X-ray	were	normal.	Blood	tests	for	fasting	
glucose,	lipid,	renal	and	liver	function	test,	complete	blood	picture,	clotting,	erythrocyte	sedimentation	
rate	were	normal.	Immune	markers	(ANA,	DNA,	ENA,	and	ANCA)	were	negative.	Anti-cardiolipin	antibody,	
protein	C	and	S,	and	anti-thrombin	III	were	also	normal.	Magnetic	resonance	 imaging	of	 the	brain	
showed	old	infarcts	at	bilateral	paramedian	thalami	and	left	rostral	midbrain	(Figs	2	and	3)	suggesting	
old	infarction	from	occlusion	of	artery	of	Percheron.	Moreover,	multiple	lacunar	infarcts	were	noted	in	
bilateral	corona	radiata,	frontal	and	parietal	white	matter,	left	temporal	lobe	and	left	centrum	semiovale.	
Magnetic	resonance	angiography	of	the	cerebral,	carotid	and	vertebral	arteries	were	unremarkable	(Fig	
4).	Thorough	investigations	for	her	young	stroke	including	carotid	duplex	ultrasound	and	transcranial	
Doppler	(TCD)	ultrasound,	transthoracic	echocardiogram	as	well	as	Holter	test	were	all	unremarkable.	
Bubble	TCD	was	 then	performed	that	revealed	one	microembolic	signal	after	Valsalva	manoeuvre	
suggestive	of	low-grade	right-to-left	shunt.	Transesophageal	echocardiogram	was	finally	performed	which	
confirmed	the	presence	of	patent	foramen	ovale	that	can	account	for	her	prior	stroke.	
	 She	has	been	given	clopidogrel	75	mg	daily	orally	since	2010	as	she	has	aspirin	allergy.	She	delivered	a	
normal	baby	uneventfully	in	June	2011.	She	has	not	had	stroke	recurrence.
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Clinical and Genetic Evaluation of 23 Children with Infantile-onset Epileptic 
Encephalopathy
Alvin CC Ho, Anna KY Kwong, CW Fung, Virginia CN Wong
Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Queen Mary Hospital / Duchess of Kent 
Children’s Hospital, Hong Kong SAR
Background:	 Infantile	epileptic	encephalopathies	(IEE)	are	a	group	of	conditions	 in	which	cognitive,	
sensory,	and/or	motor	functions	deteriorate	as	a	consequence	of	epileptic	activities,	which	consist	of	
frequent	seizures	and/or	major	interictal	paroxysmal	activity.	There	are	various	causes	of	IEE	and	they	may	
occur	at	any	age.	
Methods:	We	reviewed	patients	 in	 the	Department	of	Paediatrics	and	Adolescent	Medicine	of	 the	
University	of	Hong	Kong,	Queen	Mary	Hospital	and	Duchess	of	Kent	Children’s	Hospital	with	the	clinical	
diagnosis	of	IEE	of	unknown	aetiology	over	a	10-year	period	(2003-2012).	Five	genes	(ARX, CDKL5, KCNQ2, 
SCN1A,	and	STXBP1)	were	screened	using	sequencing.	
Results:	A	total	of	23	patients	were	identified	and	their	electroclinical	features	were	studied.	Of	the	23	
patients,	10	(43.5%)	had	epileptic	spasm	as	the	presenting	seizure	type.	Throughout	the	clinical	course,	
patients	were	characterised	by	frequent	seizures	that	were	multiform	and	pharmaco-resistant.	The	
commonest	subsequent	seizure	type	was	generalised	tonic/clonic/tonic-clonic	seizure	(17	out	of	23,	
73.9%).	All	of	the	patients	had	developmental	delay	of	various	degrees.	Movement	disorder	in	terms	of	
dystonia	was	the	most	common	associated	clinical	feature	(10	out	of	23,	43.5%).	Five	genes	(ARX, CDKL5, 
KCNQ2, SCN1A,	and	STXBP1)	were	screened	in	20	of	our	patients.	We	identified	three	patients	with	
STXBP1	mutations,	 two	patients	with	SCN1A	mutations,	and	one	patient	with	KCNQ2	mutation.	The	
overall	detection	rate	was	30%	(6/20).	Two	out	of	three	patients	with	Dravet	phenotype	were	screened	
positive	for	SCN1A	mutation.	The	only	patient	with	typical	Ohtahara	phenotype	was	screened	positive	for	
STXBP1	mutation.	
Conclusion: This	study	highlighted	the	clinical	characteristics	of	IEE	and	studied	the	yield	of	mutational	
screening	of	five	selected	genes	in	this	group	of	patients.	Dravet	syndrome	and	Ohtahara	syndrome	have	
characteristic	phenotypes.	SCN1A	and	STXBP1	mutational	analysis	should	be	performed	in	children	with	
classic	presentations	of	the	above-named	conditions	respectively.	
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Morbidity and Mortality of Guillain-Barré Syndrome in Hong Kong
Anna HY Wong
Department of Medicine, Queen Elizabeth Hospital, Hong Kong SAR
Objectives:	To	review	the	clinical	profile	and	outcome	of	patients	with	Guillain-Barré	syndrome	(GBS)	
managed	in	hospitals	 in	Hong	Kong	and	to	 look	for	any	predictors	for	mechanical	ventilation,	poor	
disability	outcome,	and	mortality.
Methods:	Subjects	suffering	from	GBS	admitted	to	Queen	Elizabeth	Hospital,	Princess	Margaret	Hospital,	
and	Caritas	Medical	Centre	from	January	2001	to	December	2010	were	included.	Patients	younger	than	18	
years	old	or	suffering	from	neuropathy	other	than	GBS	or	incomplete	medical	record	available	for	review	
were	excluded.	A	multivariate	analysis	was	used	for	analysis	of	predictors	of	outcome.
Results:	A	total	of	104	patients	were	included.	When	comparing	between	cohorts	of	three	hospitals,	they	
showed	similar	baseline	characteristics	and	outcome.	Higher	Erasmus	GBS	outcome	score	and	Erasmus	
GBS	respiratory	insufficiency	score	were	associated	with	poorer	outcome,	though	the	association	was	
not	always	statistically	significant	among	three	cohorts.	GBS	disability	score	on	admission	and	age	
were	significant	predictors	of	mechanical	ventilation	(odds	ratio=3.0;	95%	confidence	interval,	1.64-5.52;	
P<0.0001)	and	mortality	(odds	ratio=1.1;	confidence	interval,	1.03-1.17;	P=0.007),	respectively.	No	significant	
predictor	could	be	identified	for	independency	of	daily	living	at	6	months.
Conclusion:	The	median	age	and	mortality	rate	of	GBS	in	Hong	Kong	was	higher	when	compared	to	
those	of	previous	studies.	Among	the	three	local	hospitals	studied,	baseline	characteristics	and	outcome	
were	similar.	Age	and	GBS	disability	score	on	admission	were	significantly	related	to	mortality	and	risk	
of	mechanical	ventilation	respectively	while	Erasmus	GBS	outcome	score	and	Erasmus	GBS	respiratory	
insufficiency	score	on	admission	can	serve	as	a	reference	in	predicting	outcome	of	patients	with	GBS.
Intracerebral Haemorrhage in Patients Warfarinised for Non-valvular Atrial 
Fibrillation (NVAF) and the Use of HAS-BLED Score in Addition to CHA2DS2-VASc 
Score to Refine the Decision on Anticoagulation for NVAF Patients
MK Fong
Department of Medicine and Geriatrics, Princess Margaret Hospital, Hong Kong SAR
Background: Atrial	fibrillation	(AF)	can	result	 in	catastrophic	thromboembolic	complications.	Warfarin	
reduces	thromboembolic	risk	but	is	underutilised	for	the	fear	of	major	bleeding.	CHA2DS2-VASc	and	
HAS-BLED	scores	are	helpful	for	risk	stratification.
Objectives: Part	I—To	compare	the	CHA2DS2-VASc	and	HAS-BLED	scores	among	warfarinised	non-valvular	
AF	(NVAF)	patients	with	and	without	intracerebral	haemorrhage	(ICH).	Part	II—To	study	the	clinical	course	
and	outcome	of	warfarin-related	ICH.
Methods:	Three	patient	groups	in	Princess	Margaret	Hospital	(PMH),	Queen	Elizabeth	Hospital	(QEH),	
and	Caritas	Medical	Centre	(CMC)	were	retrospectively	studied:	Case—warfarinised	NVAF	patients	with	
ICH	(PMH/QEH/CMC)	during	1	January	2006	to	31	December	2011;	Part	I	reference—warfarinised	NVAF	
patients	(PMH)	without	ICH	during	1	July	2011	to	31	October	2011;	Part	II	control—non-warfarin	ICH	
patients	(PMH)	matched	with	the	case	group	for	gender,	age	(±	1	year),	and	admission	year,	in	one-to-one	
ratio.
Results:	 In	Part	 I,	114	cases	and	661	references	were	recruited.	The	case	group	had	a	higher	median	
CHA2DS2-VASc	score	(5	vs	4;	P=0.011)	and	more	patients	in	high-bleeding	risk	category	than	reference	
group	(46.5%	vs	36.6%;	P=0.033).	Most	anticoagulated	patients	 (99.1%)	had	appropriate	benefit-risk	
balance.	In	Part	II,	the	mean	admission	international	normalised	ratio	(INR)	was	2.8.	Eighty-two	(73.2%)	
patients	had	ICH	despite	admission	INR	did	not	exceed	therapeutic	range	(INR	≤3.0).	Initial	ICH	volumes	
were	comparable	among	case	and	control	groups.	A	majority	of	patients	 in	both	groups	had	poor	
functional	outcome	at	6	months.	Warfarin-related	ICH	had	a	higher	in-patient	mortality	(51.8%	vs	36.0%;	
P=0.02)	and	6-month	mortality	(60.5%	vs	43%;	P=0.01)	than	non-warfarin	ICH.	Lower	admission	Glasgow	
Coma	Scale	score	(P=0.001),	higher	initial	ICH	volume	(P=0.003),	and	higher	ICH	score	(P<0.001)	were	
predictors	of	poor	outcome.
Conclusion:	Warfarin-related	ICH	in	NVAF	patients	had	significant	morbidity	and	mortality.	CHA2DS2-VASc	
score	and	HAS-BLED	score	are	useful	risk	stratification	tools	to	guide	treatment	in	NVAF	patients.
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Study on the Safety and Efficacy of Dabigatran Etexilate (Pradaxa®) in Stroke 
Prevention on Hong Kong Chinese with Atrial Fibrillation as Compared with  
Warfarin: a Local Hospital Experience
KK Ma
Department of Medicine, North District Hospital, Hong Kong SAR
Background:	The	use	of	anticoagulant	for	stroke	prevention	in	atrial	fibrillation	is	raising	concern	in	Hong	
Kong.	Warfarin	was	the	only	oral	anticoagulant	available	in	the	market	before	the	launch	of	dabigatran	
etexilate.	The	benefit	of	new	anticoagulant	is	reported	as	non-inferior	to	warfarin	on	stroke	prevention.	
Besides,	patients	would	benefit	from	less	food-and-drug	restriction	in	view	of	relative	less	interaction.	
Thus,	it	can	provide	a	relative	stable	anticoagulation	effects	compared	with	warfarin.	However,	there	are	
no	local	data	on	the	efficacy	and	safety	on	the	use	of	dabigatran	etexilate	in	Hong	Kong.
Objective:	To	study	the	safety	and	efficacy	of	dabigatran	etexilate	in	stroke	prevention	on	Hong	Kong	
Chinese	with	atrial	fibrillation.
Methods:	This	was	a	retrospective	phase	IV	postmarket	study.	Patients	on	dabigatran	etexilate	from	
medical	specialist	out-patient	clinic	in	North	District	Hospital	between	January	2009	and	August	2012	were	
recruited	in	the	study.	The	safety	issue	of	the	dabigatran	etexilate	was	defined	as	the	incidence	of	major	
bleeding	including	intracranial	haemorrhage,	and	minor	bleeding,	gastro-intestinal	complications	and	
hypersensitivity	reaction.	The	efficacy	of	the	dabigatran	etexilate	was	investigated	by	patient	outcomes.	
The	primary	outcome	was	recurrent	 ischaemic	stroke	or	transient	 ischaemic	attack.	The	secondary	
outcome	was	the	mortality	incidence.	The	overall	data	were	compared	with	Asian	and	non-Asian	data	
from	RELY	study	upon	the	dabigatran	treatment	arms	and	warfarin	arm.	The	data	were	reviewed	by	
February	2013.
Results:	A	total	of	96	patients	were	enrolled	in	the	study.	The	mean	follow-up	period	was	16	months.	Our	
patients	were	more	advance	in	age	and	multiple	co-morbidities	with	higher	CHADS2	scores.	The	stroke	
rate	was	3.37%	per	year	which	was	higher	when	compared	with	the	dabigatran	treatment	and	warfarin	
arm	in	RELY	study	as	1.39%	and	2.50%	per	year,	respectively.	Four	patients	got	interrupted	dabigatran	use	
before	the	stroke	events.	The	mortality	rate	was	3.37%	per	year	as	compared	with	dabigatran	treatment	
and	warfarin	arm	in	RELY	study	as	4.01%	and	5.01%	per	year,	respectively.	The	major	and	minor	bleeding	
risks	were	4.69%	and	1.56%,	 respectively,	which	were	 lower	when	compared	with	 the	dabigatran	
treatment	arm	and	warfarin	arm	in	RELY	study.	
Conclusions:	The	mortality	and	major	adverse	event	rates	were	comparable	between	our	study	data	and	
the	RELY	study	in	the	Asian	group	and	non-Asian	group.	The	higher	stroke	rate	in	our	study	may	be	
related	to	the	interrupted	dabigatran	use	such	as	prolonged	drug	withdrawal	before	procedure,	after	
minor	bleeding	or	inappropriate	dosage.	Further	study	with	larger	sample	size,	longer	study	period,	and	
comparable	control	arm	are	recommended.	
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DH 4Acute Ischaemic Stroke in Patients with Atrial Fibrillation and Their Use of  
Warfarin
Eric YC Leung
Department of Medicine, Ruttonjee Hospital, Hong Kong SAR
Objectives:	Atrial	fibrillation	(AF)	is	a	strong	independent	risk	factor	for	ischaemic	stroke	(IS).	Current	
guidelines	suggest	anticoagulation	as	a	class	1A	recommendation	for	patients	with	IS	and	AF	(IS/AF).	We	
investigated	any	difference	between	IS	patients	with	and	without	AF,	and	factors	associated	with	their	
initiation	and	continuation	of	warfarin.
Methods:	A	cross-sectional	retrospective	study	utilising	the	stroke	registry	of	Pamela	Youde	Nethersole	
Eastern	Hospital	from	2009	to	2010	was	conducted.	A	total	of	824	IS	patients	with	AF	(n=216)	and	without	
AF	(n=608)	were	examined	for	difference	in	demographics,	stroke	subtypes,	stroke	severity,	treatments,	
and	outcomes.	Univariate	analysis	was	used	to	determine	any	association(s)	with	increased	likelihood	
of	1-year	re-stroke	or	death.	Warfarin	prescription,	its	use	against	the	CHADS2	scores,	reason(s)	for	not	
prescribing	warfarin,	warfarin	initiation	and	termination	in	the	year	post-discharge	were	examined	in	IS/
AF	patients.	
Results:	Our	IS/AF	patients	were	older,	more	likely	to	be	female,	to	have	ischaemic	heart	disease	and	
more	severe	stroke,	to	receive	acute	thrombolysis,	and	were	more	disabled	by	their	stroke.	A	NIHSS	
score	of	≥5	on	discharge,	age	≥80	years,	Glasgow	Coma	Scale	score	 (GCS)	≤12,	and	mRS	≥4	were	
associated	with	 increased	 likelihood	of	1-year	mortality.	Only	61	(32.1%)	of	 the	IS/AF	patients	were	
prescribed	warfarin	on	discharge;	warfarin	prescription	was	highest	in	patients	with	CHADS2	score	of	
2.	Nine	(8.0%)	of	IS/AF	patients	not	given	warfarin	on	discharge	(n=112)	 initiated	warfarin	and	seven	
(11.5%)	of	 the	warfarinised	patients	 (n=61)	stopped	warfarin,	 in	 the	year	 following	discharge.	At	12	
months,	58	(42.0%)	patients	were	still	using	warfarin.	The	three	most	frequently	documented	reasons	
for	not	prescribing	warfarin	were	poor	functional	status,	no	reason	given,	and	bleeding	risk.	60%	of	our	
warfarinised	patients	spent	100%	time	within	international	normalised	ratio	(INR)	range	of	1.5-3.0,	but	
only	12%	if	the	target	INR	range	was	2.0-3.0.
Conclusions:	The	overall	use	of	warfarin	in	our	IS/AF	patients	remained	low.	Possible	explanations	include	
clinicians	and	patient	perceptions	of	high	complication(s)	risk	with	warfarin	and	the	underestimation	of	
stroke	risk	from	AF.	Clinicians	are	encouraged	to	use	the	HAS-BLED	score	with	the	CHADS2	or	CHA2DS2-
VASc	scores	when	considering	patients	for	anticoagulation.
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Recent Advances in Stroke Imaging
PW Cheng
Scanning Department, St Teresa’s Hospital, Hong Kong SAR
With	the	advent	of	magnetic	resonance	(MR)	and	computed	tomography	(CT)	 imaging	techniques,	
imaging	has	become	an	 indispensable	 tool	 to	 the	diagnosis	and	management	of	stroke	patients.	
Advanced	stroke	imaging	also	plays	a	pivotal	role	in	selection	and	monitoring	of	patients	being	treated	by	
endovascular	or	intravenous	intra-arterial	recanalisation	therapy.	
	 Conventional	MR	imaging,	especially	 the	diffusion-weighted	sequence,	has	vastly	 improved	the	
sensitivity	and	specificity	for	detection	of	acute	stroke	as	compared	with	CT	scan	in	the	early	days.	The	
first	part	of	this	talk	will	focus	on	the	essential	pearls	and	pitfalls	in	contemporary	acute	stroke	imaging	so	
as	to	improve	diagnostic	accuracy	in	our	daily	clinical	practice	by	recognising	common	critical	artefacts.	
Neuroimaging	scores	for	acute	stroke	and	intra-cerebral	haemorrhage	will	also	be	briefly	reviewed.	
	 Secondly,	 the	continually	evolving	multi-modality	and	multi-parametric	stroke	imaging	approach	
will	be	elaborated.	Advanced	 imaging	techniques	such	as	CT	angiography,	CT	perfusion,	dynamic	
susceptibility	perfusion-weighted	MR	imaging,	arterial	spin-labelling	perfusion-weighted	MR	imaging	
are	increasingly	employed	for	triage	of	patients	for	tailored	acute	stroke	therapy	as	well	as	evaluation	of	
chronic	ischaemic	stroke.
	 Emerging	novel	stroke	imaging	techniques	such	as	diffusion	tensor	and	permeability	imaging	will	also	
be	addressed	in	the	context	of	their	potential	clinical	application.	The	various	directions	for	future	stroke	
imaging	research	will	be	highlighted,	including	non-invasive	vulnerable	plaque	imaging,	recanalisation	
strategies	over	extended	time	window	etc.
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Intracranial Stenting
WM Lui
Department of Neurosurgery, Queen Mary Hospital, Hong Kong SAR
Intracranial stent as an adjunct to endovascular embolisation/coiling
Recent	technological	advances	have	led	to	the	development	of	adjunctive	devices	and	techniques	to	
improve	the	results	with	endovascular	embolisation/coiling.	These	are	devices	that	help	coils	stay	inside	
the	aneurysm	sac	which	can	be	particularly	helpful	for	aneurysms	with	wide	necks	or	large	aneurysms	
that	were	difficult	to	treat	with	embolisation/coiling	in	the	past.
	 One	such	adjunctive	device	is	an	intracranial	stent.	A	stent	is	a	metal	mesh	device	in	the	shape	of	a	
pipe	or	tube	which	is	placed	inside	the	parent	artery	at	the	site	of	the	aneurysm	to	cover	the	neck	of	the	
aneurysm.	This	helps	to	keep	coils	placed	in	the	aneurysm	sac	to	stay	inside	the	sac.
	 The	stents	are	usually	made	of	nitinol,	a	high-grade	metal	alloy	of	nickel	and	titanium.	One	or	
more	antiplatelet	medicines	such	as	aspirin,	clopidogrel,	ticlopidine,	or	others	are	required	to	prevent	
thromboembolism	after	stent	placement.	Therefore,	the	use	of	stent	in	emergency	situation	with	prior	
antiplatelet	coverage	carries	certain	risk.	
	 At	 the	 time	of	 the	embolisation/coiling	procedure,	or	 sometimes	as	a	 separate	 treatment,	 a	
microcatheter	and	wire	are	navigated	from	the	access	site	(usually	 the	femoral	artery	 in	the	groin)	
using	X-ray	visualisation	up	to	the	site	of	the	aneurysm	in	the	brain.	The	stent	can	be	pushed	through	
the	microcatheter	and	deployed	at	the	intended	target	to	cover	the	aneurysmal	neck.	Then	another	
microcatheter	is	navigated	through	the	stent	strut	and	placed	inside	the	aneurysm	sac.	Then	coils	are	
placed	in	the	aneurysm	sac	as	would	be	performed	as	described	in	the	coiling	description.	The	stent	will	
prevent	the	coils	from	entering	the	parent	artery	and	in	so	doing,	a	complete	occlusion	of	the	aneurysm	
sac	is	made	possible.
Flow diverters—pipeline embolisation device
Approved	by	the	Food	and	Drug	Administration	in	April	2011,	the	pipeline	embolisation	device	(PED)	
is	a	flexible	mesh	tube	made	of	platinum	and	nickel-cobalt	chromium	alloy	that	can	be	used	to	block	
off	large,	giant,	or	wide-necked	aneurysms	in	the	intracranial	arteries.	The	device	can	also	reduce	the	
likelihood	that	an	aneurysm	will	rupture.	
	 To	implant	the	device,	the	pipeline	is	attached	to	the	end	of	a	catheter.	The	catheter	is	threaded	into	
the	carotid	artery	and	into	position	at	the	aneurysm	where	the	pipeline	is	expanded	against	the	walls	
of	the	artery	and	across	the	neck	of	the	aneurysm,	cutting	off	blood	flow	to	the	aneurysm.	The	blood	
remaining	in	the	blocked-off	aneurysm	forms	a	clot	which	reduces	the	likelihood	the	aneurysm	will	grow	
bigger	or	rupture.	Aneurysms	successfully	treated	with	the	pipeline	will	often	shrink	over	time.	
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Clinical Use of Electroencephalography: Ten Years After the Millennium
Ziyi Chen
Department of Neurology, The First Affiliated Hospital, Zhongshan (Sun Yat Sen) University, PR China
The	electroencephalography	(EEG),	which	is	entirely	harmless	and	relatively	inexpensive,	 is	the	most	
important	 investigation	 in	 the	diagnosis	of	epilepsies.	 In	2001,	 ILAE	Task	Force	established	a	new	
diagnostic	scheme	for	people	with	epileptic	seizures	and	with	epilepsy:	ictal	phenomenology,	seizure	
type,	syndrome,	aetiology,	and	impairment.	I	am	going	to	show	some	examples	of	clinical	use	of	EEG	
in	the	new	diagnostic	scheme.	First,	the	paroxysmal	event	should	be	differentiated	between	epileptic	
seizure	and	non-epileptic	attack.	Since	the	epileptic	seizure	has	been	defined	as	a	transient	occurrence	of	
sign	and/or	symptoms	due	to	abnormal	excessive	neuronal	activity	in	the	brain,	synchronous	EEG	may	be	
the	key	method	for	differentiation.	We	should	pay	attention	to	those	patients	with	real	epileptic	seizure	
and	pseudoseizures.	Second,	the	type	of	epileptic	seizures	should	be	confirmed.	Video-EEG	is	particularly	
important	in	the	identification	and	categorisation	of	epileptic	seizures.	Here	I	am	going	to	share	both	
some	typical	cases	of	classic	epileptic	seizure	types	(such	as	generalised	tonic-clonic	seizure,	absence	
seizure,	atonic	seizure),	and	some	new	types	(such	as	eyelid	myoclonia).	Third,	the	epileptic	syndrome	or	
epileptic	disease	should	be	clearly	diagnosed.	The	epileptic	syndrome	is	defined	as	an	epileptic	disorder	
characterised	by	a	cluster	of	signs	and	symptoms	customarily	occurring	together.	There	are	different	
characteristics	in	different	epileptic	syndrome.	For	example,	electrical	status	epilepticus	in	sleep	(ESES)	
is	related	to	Landau-Kleffner	syndrome	(acquired	epileptic	aphasia)	and	epilepsy	with	continuous	spike-
and-waves	during	slow-wave	sleep	(ECSWS).	In	summary,	EEG	recording	is	of	great	diagnostic	significance	
in	clinical	practices	because	it	is	associated	with	clinical	manifestations.	
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S 4The Mechanism of Neural Tube Defects Induced by Antiepileptic Drugs
Liemin Zhou
Neurological Department, The First Affiliated Hospital, Sun Yet-Sen University, Guangzhou 510080, PR China
Neural	tube	defects	(NTDs)	are	among	the	most	prevalent	and	most	severe	congenital	malformations	
worldwide.	Polymorphisms	 in	key	genes	 involving	 the	 folate	pathway	have	been	reported	 to	be	
associated	with	the	risk	of	NTDs.	Valproic	acid	(VPA)	is	one	of	the	firstline	antiepileptic	drugs	(AEDs)	and	
widely	used	to	control	most	subtypes	of	seizures.	Some	women	with	epilepsy	during	pregnancy	need	to	
be	treated	by	VPA,	which	however	will	increase	the	risk	of	NTDs	from	the	data	of	EURAP	and	the	North	
American	AED	Pregnancy	Registry.	At	present,	the	teratogenic	mechanism	induced	by	VPA	is	still	unclear.	
Both	the	genetic	polymorphism	of	folate	metabolic	enzymes	and	valproic	acid	therapy	can	affect	gene	
transcription	through	histone	hyperacetylation,	DNA	hypomethylation	and	the	modulation	of	several	
transcription	factors,	which	may	play	an	important	role	in	neural	tube	closure	in	sensitive	patients	via	
mediating	the	gene	expression.	In	this	 lecture,	we	will	analyse	the	role	of	genetic	polymorphisms	of	
folate	matabolic	enzymes,	and	DNA	methylation	and	inhibition	of	histone	deacetylases	(HDACs)	in	NTDs	
induced	by	VPA,	and	explore	the	mechanism	of	NTDs	caused	by	VPA.
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Ketogenic Diet / Modified Atkins Diet for Epilepsy
Phyllis YP Yau1, Eva LW Fung2
1 Dietetics Department and 2 Department of Paediatrics, Prince of Wales Hospital, Hong Kong SAR
Ketogenic	diet	has	been	used	for	treating	epilepsy	for	almost	100	years.	The	utilisation	and	interests	in	the	
diet	and	its	modification/variation	are	increasing	in	the	past	decade.	With	more	clinical	experience	and	
scientific	documentation	of	its	efficacy,	its	uses	have	also	been	included	in	latest	NICE	guidelines.	There	
are	also	reports	of	implementing	the	diet	in	the	acute	setting,	especially	in	cases	with	super-refractory	
status	epilepticus.	Some	of	the	greatest	hurdles	in	implementing	the	ketogenic	diet	are	the	restriction	in	
food	intake,	labour-intensive	implementation,	and	maintenance	of	the	diet	and	concerns	on	theoretical	
health	risks	associated	with	the	diet.	The	development	of	 less	‘stringent’	alternatives,	 like	modified	
Atkins	diet	and	low	glycaemic	index	diet,	have	become	much	more	attractive,	especially	for	adults.	They	
are	much	easier	to	implement	and	maintain,	both	for	the	patients	and	clinicians/dietitians.	There	is	no	
restriction	in	mealtimes,	calories,	and	liquid,	etc.	Studies	have	also	demonstrated	the	efficacy	in	both	
children	and	adults.	Besides	uses	in	epilepsies,	new	applications	of	ketogenic	diet	therapies	for	other	
medical	conditions	have	also	been	explored,	including	amyotrophic	lateral	sclerosis,	diabetic	neuropathy,	
and	malignant	brain	tumours,	etc.	
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Management of Gait Disorders in Parkinson’s Disease: a Neurologist’s  
Perspective
Germaine HF Chan
Department of Medicine, Queen Elizabeth Hospital, Hong Kong SAR
Gait	and	balance	disorder	is	a	common,	yet	debilitating	problem	in	Parkinson’s	disease	(PD)	patients.	The	
Sydney	multicentre	study	showed	a	high	fall	risk	of	87%	in	advanced	PD	patients,	resulting	in	fractures	
and	immobilisation.	A	recently	published	Chinese	study	also	reproduced	similar	results.	Therefore,	
it	 is	 important	to	understand	the	pathophysiological	mechanism,	detect	the	risk	factors,	and	provide	
appropriate	treatment.
Pathophysiological mechanism of gait and balance disorders in Parkinson’s disease 
Gait	and	balance	dysfunction	can	occur	in	any	stages	of	PD,	even	though	it	is	more	common	in	advanced	
PD	patients.	 In	early	PD,	dopamine	deficiency	accounts	 for	 these	axial	symptoms.	Nonetheless,	 in	
advanced	PD,	gait	disorder	is	more	complex	and	is	 likely	to	involve	both	the	dopaminergic	and	non-
dopaminergic	pathways.	Besides,	difficulty	in	multi-tasking,	impaired	sensorimotor	integration,	as	well	as	
a	lack	of	compensatory	stepping,	may	contribute	to	a	higher	incidence	of	falls	in	PD	patients.
Risk factors of falls in Parkinson’s disease
A	history	of	two	or	more	falls	in	the	previous	year	is	found	to	be	the	best	predictive	factor	of	falls	in	PD	
patients.	Impaired	ambulation,	poor	lower	limb	motor	planning,	and	orthostasis	also	predict	gait	and	
balance	problems.	
Management of gait and balance disorders in Parkinson’s disease
Axial	symptoms	in	parkinsonism	can	be	divided	into	two	groups:	dopamine	responsive	and	dopamine	
resistant.	In	early	PD	patients,	when	dopamine	deficiency	is	responsible	for	these	symptoms,	stepping	
up	dopaminergic	medications	 is	 the	solution.	 In	advanced	PD	patients,	 the	gait	disorders	are	more	
complicated	and	are	often	refractory	to	dopaminergic	treatment.	In	this	case,	drugs	targeting	on	the	non-
dopaminergic	system,	such	as	methylphenidate	and	amantadine,	may	be	useful	to	improve	the	gait	and	
balance	issues.	
S 6
Hong Kong Med J Vol 19 No 6 # Supplement 6 # December 2013      21
The Therapeutic Effect of Hepcidin in Parkinson’s Disease Via Regulation of  
Brain Iron and α-Synuclein Accumulation 
Ya Ke
School of Biomedical Sciences, Faculty of Medicine and Shenzhen Research Institute, The Chinese University of Hong Kong, Hong 
Kong SAR
Experimental	 and	clinical	evidence	suggest	 that	 abnormal	 iron	accumulation	 is	 involved	 in	 the	
pathogenesis	of	Parkinson’s	disease	(PD).	Since	the	hormone	hepcidin	is	the	main	regulator	of	body	
iron	 level,	 including	that	 in	the	brain,	we	hypothesise	that	hepcidin	offers	 therapeutic	potential	 in	
Parkinsonism.	We	tested	our	hypothesis	based	on	a	rat	model	of	PD	via	chronic	injection	of	rotenone.	In	
this	model	that	captures	the	clinical	features	of	PD	with	respect	to	α-synuclein	accumulation	as	well	as	
the	progressive	nature	of	the	disorder,	we	found	that	chronic	rotenone	treatment	resulted	in	selective	
accumulation	of	α-synuclein	and	iron	in	the	substantia	nigra	pars	compacta,	which	was	accompanied	by	
degeneration	of	dopamine	neurons.	The	motor	ability,	assessed	by	the	open	field	test	and	grid	test,	was	
also	significantly	reduced.	Injection	of	the	adenovirus-hepcidin	starting	on	day	5	into	the	lateral	cerebral	
ventricle	could	significantly	rescue	the	motor	deficit	 induced	by	rotenone.	Postmortem	examination	
and	in-vitro	experiments	revealed	that	the	over-expressed	hepcidin	could	suppress	α-synuclein	and	iron	
accumulation,	and	reduced	neuronal	toxicity.	Together,	these	results	strongly	suggest	that	manipulating	
the	level	of	the	hepcidin	could	be	a	promising	therapeutic	strategy	for	PD.
	 This	work	was	supported	by	the	National	973	Program	(2011CB510004);	CUHK	Direct	Grant	(4054042).
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Rehabilitation of Gait Disorders in Parkinson’s Disease
Margaret Mak
Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong SAR
Walking	difficulty	is	one	of	the	cardinal	signs	leading	to	disabilities	in	people	with	Parkinson’s	disease	(PD).	
PD	patients	manifest	continuous	gait	impairment	such	as	reduced	stride	length,	reduced	gait	speed,	and	
increased	stride	time	variability	and/or	episodic	gait	disorders	such	as	freezing	of	gait,	which	predispose	
them	to	falls.	In	fact,	walking	is	the	most	common	fall-related	activity	among	PD	patients.	Physiotherapists	
play	an	important	role	in	the	rehabilitation	of	walking	which	includes	both	evaluation	and	treatment.	Gait	
assessment	is	carried	out	to	understand	the	biomechanical	mechanisms	underlying	gait	disorders	so	as	
to	design	appropriate	treatment	strategies	as	well	as	to	evaluate	treatment	outcomes.	Numerous	studies	
have	found	that	the	use	of	external	cues	results	 in	immediate	improvement	of	stride	length,	walking	
speed,	and	walking	pattern.	These	cues	include	auditory	cues,	visual	cues,	tactile	cues,	or	cognitive	cues.	
There	are	preliminary	reports	on	the	benefits	of	external	cues	on	enhancing	dual	cognitive-walking	and	
turning	tasks.	In	addition	to	cued	training,	gait	training	on	a	treadmill	has	been	found	to	increase	walking	
speed	and	reduce	variability	of	gait	and	freezing	of	gait.	Recent	studies	reported	the	effects	of	non-
invasive	brain	stimulation	techniques	such	as	repetitive	transcranial	magnetic	stimulation	on	enhancing	
walking	performance	 in	PD	patients.	Research	evidence	on	 these	approaches	and	 the	proposed	
mechanisms	will	be	presented.	
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Mechanism of Deep Brain Stimulation in Parkinsonism: Direct Involvement of  
the Primary Motor Cortex
WH Yung 
School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR
High-frequency	deep	brain	stimulation	(DBS)	applied	to	the	subthalamic	nucleus	(STN)	has	proved	to	
be	useful	in	treating	Parkinson’s	disease	(PD),	but	its	mechanism	remains	enigmatic.	In	principle,	DBS	
can	directly	activate	a	wide	range	of	neuronal	elements	in	the	target	and	surrounding	areas,	including	
neuronal	soma,	nerve	terminals	and	axons	of	passage.	We	hypothesise	that	abnormal	activities	in	the	
primary	motor	cortex	play	a	critical	role	in	the	manifestation	of	PD	symptoms	and	could	be	a	target	
of	DBS.	To	enable	us	to	address	this	question	on	an	animal	model	of	PD,	we	made	recordings	of	both	
single-unit	activities	and	local	field	potentials	in	the	motor	cortex	of	freely	moving	hemi-Parkinsonian	
rats	before,	during,	and	after	STN-DBS.	In	these	movement-disabled	animals,	abnormal	beta	rhythm	in	
the	motor	cortex	was	found,	which	was	accompanied	by	marked	increase	in	burst	firing	and	synchrony	
among	 layer	V	motor	cortical	projection	neurons.	During	 the	delivery	of	STN-DBS,	we	 identified	
short-latency	antidromic	spikes	in	layer	V	neurons.	Intriguingly,	 increased	failure	rate	with	increasing	
stimulation	frequency	produced	the	highest	number	of	random	antidromic	spikes	at	125	Hz	stimulation,	
which	correlated	with	the	optimal	therapeutic	efficacy	on	these	animals.	This	effect	was	accompanied	by	
increased	firing	rate,	reduced	burst	spiking	and	synchrony	of	firing	in	the	motor	cortical	neurons.	Field	
potential	analysis	revealed	normalisation	of	the	pathological	beta	rhythm.	Importantly,	we	found	evidence	
that	the	firing	probability	of	the	cortical	projection	neuron	was	modified	following	the	occurrence	of	
an	antidromic	spike	suggesting	that	direct	interference	of	synchronised	firing	by	stochastic	antidromic	
spikes	underlies	the	beneficial	effect.	Our	results	therefore	support	that	STN-DBS	antidromically	activates	
output	neurons	in	the	motor	cortex	through	the	corticosubthalamic	nucleus	projection,	which	directly	
disrupts	abnormal	neural	activities	in	the	motor	cortex	in	PD.	Although	direct	stimulation	of	the	motor	
cortex	in	patients	is	still	controversial,	our	results	highlight	that	given	a	suitable	stimulation	paradigm,	the	
motor	cortex	could	be	a	potential	target	for	the	treatment	of	PD.
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Spinocerebellar Ataxia in Chinese
Anne YY Chan1, Edwin HY Chan2
1 Department of Medicine and Geriatrics, Prince of Wales Hospital, Hong Kong SAR
2 School of Life Sciences, Faculty of Science, The Chinese University of Hong Kong, Hong Kong SAR
Spinocerebellar	ataxias	 (SCA)	1,	2,	3	and	6	are	 the	most	common	autosomal	dominantly	 inherited	
cerebellar	degenerations.	In	the	Chinese	population,	the	most	common	SCA	is	SCA3	and	the	frequency	
of	SCA3	among	SCA	patients	is	72.5%,	followed	by	SCA2	with	the	frequency	of	12%	among	SCA	patients.	
For	SCA1,	the	frequency	among	SCA	patients	is	7%.	Even	though	SCAs	are	rare	diseases,	a	significant	
number	of	Chinese	 in	Hong	Kong	still	suffer	from	this	disorder.	Hong	Kong	Spinocerebellar	Ataxia	
Association	has	88	members	who	are	suffering	from	cerebellar	degeneration,	many	of	them	have	a	
genetic	confirmation.	
	 As	there	are	few	treatments	for	SCA,	understanding	its	clinical	manifestation	and	disease	mechanisms	
is	the	first	step	towards	development	of	effective	treatment.	In	Europe	and	North	America,	two	largest	
SCA	consortia	involving	many	medical	centres,	European	SCA	group	(EUROSCA),	and	Clinical	Research	
Consortium	for	Spinocerebellar	Ataxias	(CRC-SCA)	have	established	bio-repository	banks	to	collect	SCA	
patients’	clinical	and	genetic	information	as	well	as	the	natural	history	of	SCAs.	From	the	natural	history	
studies	of	SCA1,	2,	3,	6,	and	7,	of	these	two	consortia,	 they	also	developed	Scale	for	the	Assessment	
and	Rating	of	Ataxia	(SARA),	which	is	a	validated	clinical	tool	to	reliably	quantify	the	degree	of	ataxia	
symptoms.	However,	we	do	not	have	a	centralised	ataxia	centre	collecting	such	 information	and	
specimen	in	Hong	Kong.	Establishing	an	ataxia	registry	for	clinical	and	genetic	information	in	Hong	Kong	
will	facilitate	the	ataxia	research	worldwide.
	 Spinocerebellar	ataxias	 (SCAs)	are	a	group	of	genetically	diverse	neurodegenerative	disorders	
causing	cerebellar	degeneration	and	progressive	ataxia.	There	are	currently	36	types	of	SCA	reported	but	
only	21	disease-causing	genes/mutations	have	been	determined.	Identifying	the	underlying	mutations	
enables	mechanistic	investigation	of	pathogenesis	and	subsequent	therapeutic	development	of	SCAs.	
By	performing	exome	and	whole-genome	sequencing	on	multiple	family	members	of	an	autosomal	
dominant	SCA	family,	we	identified	a	single-point	mutation	in	the	coding	region	of	a	protein-coding	
gene	in	all	affected	individuals.	Further,	this	mutation	was	not	observed	in	over	200	control	genomes	
collected	in	the	local	population.	Clinically,	 the	patients	exhibited	typical	cerebellar	ataxia	signs	and	
magnetic	resonance	imaging	showed	obvious	pontocerebellar	atrophy	along	with	a	global	reduction	in	
brain	volume.	Since	no	known	SCA	has	previously	been	assigned	to	the	genetic	locus	of	the	identified	
mutation,	our	study	unveiled	a	novel	 form	of	autosomal	dominant	type	of	SCA	and	we	named	this	
condition	SCA37.
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Identification and Characterisation of a Cognitive Enhancer from Traditional  
Chinese Medicine
Fanny CF Ip, Nancy Y Ip
State Key Laboratory of Molecular Neuroscience, Division of Life Science, The Hong Kong University of Science & Technology, Hong 
Kong SAR
Neurodegenerative	diseases,	characterised	by	progressive	loss	of	neurons,	are	emerging	to	become	
a	major	health	burden	in	societies	with	a	large	ageing	population.	Increasing	evidence	suggests	that	
synaptic	dysfunction	plays	a	key	role	in	the	onset	and	progression	of	neurodegenerative	diseases.	To	
this	end,	we	have	leveraged	our	research	strengths	in	molecular	neuroscience	and	Chinese	medicine	to	
establish	a	focused	drug	discovery	programme	in	search	of	novel	drug	leads,	including	those	that	can	
regulate	synaptic	activity.	We	report	here	the	discovery	of	a	multivalent	herb-derived	compound,	which	
modulates	function	of	the	AMPA-type	of	glutamate	receptor	by	increasing	serine	phosphorylation	of	
AMPA	receptor	subunit	GluA1,	which	is	important	for	trafficking	GluA1-containing	AMPA	receptors	to	
the	synapses.	Administration	of	this	compound	activates	an	array	of	signalling	pathways	that	are	critical	
for	synaptic	plasticity,	 resulting	 in	 increased	protein	expression	of	 the	neurotrophin	brain-derived	
neurotrophic	 factor	and	enhanced	 level	of	monoamine	neurotransmitters	 in	mouse	hippocampus.	
Furthermore,	 this	compound	can	 rescue	 impaired	 long-term	potentiation	 in	brain	 slices	either	
treated	with	amyloid-beta	oligomers	or	 isolated	 from	Tg2576	Alzheimer’s	disease	mouse.	 In	vivo,	
this	compound	enhances	the	reference	memory	of	mice	in	the	Morris	water	maze	task,	reduces	the	
duration	of	 immobility	 in	the	forced	swim	test,	and	rescues	neurological	deficits	 in	a	stroke	model.	
These	observations	suggest	that	this	compound	is	an	attractive	candidate	for	development	as	a	cognitive	
enhancer	to	alleviate	memory	dysfunctions	associated	with	ageing	and	neurodegenerative	diseases.
	 The	study	is	supported	in	part	by	National	Basic	Research	Program	of	China	(973	Program),	Shenzhen	
Peacock	Plan,	the	Hong	Kong	Research	Grants	Council	Theme-based	Research	Scheme	(T13-607/12R),	and	
Innovation	and	Technology	Fund	[State	Key	Laboratory	(ITCPT/17-9)].
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Individualised Stem Cell Therapy
Ken KL Yung
Department of Biology, Hong Kong Baptist University, Hong Kong SAR
Neurodegenerative	diseases	including	Alzheimer’s	and	Parkinson’s	diseases	can	cripple	lives	to	varying	
degrees:	 from	minor	disability	 to	 loss	of	movement	or	memory.	At	present,	 there	are	only	 limited	
therapies	for	neurodegenerative	diseases.	Research	in	neural	stem	cell	and	regenerative	medicine	using	
functional	neural	stem	cells	from	adult	human	brain	is	currently	hindered	due	to	risks	with	brain	surgery	
and	the	uncertainty	in	the	location	of	extraction.	Herein,	we	have	adopted	latest	interdisciplinary	designs	
and	then	combine	the	novel	nanomaterials	 to	develop	an	 innovative	treatment.	We	demonstrate	a	
simple	magnetic	separation	method	for	the	single-step	extraction	of	stem/progenitor	cells	from	choroid	
plexus	 lining	along	the	subventricular	zone	by	applying	antibodies-conjugated	magnetic	 iron	oxide	
nanoparticles	(Ab-MNPs)	to	the	corresponding	region	in	a	rat	brain	with	a	superfine	micro-syringe.	It	
is	shown	that	the	magnetically	isolated	but	active	stem	cells	can	be	developed	into	neurospheres	and	
differentiated	into	different	types	of	cells	 in	culture	medium	in-vitro	outside	the	subject	body.	This	
unique	characteristic	leads	us	to	develop	a	new	tailor-made	neurological	disorder	therapy	as	the	cells	can	
be	extracted,	modified,	and	re-applied	to	the	same	subject.	As	the	cells	are	originated	from	the	patients	
themselves,	the	risk	of	immune	rejection	can	be	greatly	reduced.	We	believe	that	this	method	could	be	
adoptedable	as	a	new	tailor-made	stem	cell	therapy	by	harvesting,	engineering,	and	dosing	to	individual	
patients’	own	neural	stem	cells	for	neurological	treatments.
	 Angewandte Chemie International (DOI:	10.1002/anie.201305482)
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Intracranial Abscesses and Infections of Neurosurgical Shunts and Drains
YW Fan
Private practice, Hong Kong SAR
An	overview	of	management	of	intracranial	suppurative	infection	and	cerebrospinal	fluid	(CSF)	shunt	
catheter	infection	is	presented.	
	 Intracranial	suppurative	infections	are	life-threatening	but	eminently	treatable	conditions.	Lacking	
the	alertness	of	such	condition	can	 lead	to	delay	 in	diagnosis	and	treatment.	The	clinical	 features,	
imaging	finding,	role	of	surgery,	and	antibiotics	treatment	strategies	in	the	management	of	intracranial	
suppurative	infection	are	discussed.	With	the	increasing	popularity	of	endovascular	intervention,	we	are	
seeing	more	and	more	intracranial	infective	complications	related	to	indwelling	devices	and	intra-arterial	
administration	of	medication.	Illustrative	cases	are	presented.
	 The	second	part	of	the	presentation	is	related	to	CSF	shunt	catheter	infection.	Although	CSF	shunting	
has	been	remarked	as	the	most	successful	invention	in	the	history	of	neurosurgery,	neurosurgeons	are	
trying	hard	to	avoid	putting	in	shunts	in	their	patients	nowadays.	Shunt	catheter	infection	is	the	most	
common	complication	in	CSF	shunting	operation.	Aetiological	factors,	ways	to	avoid	catheter	infection,	
diagnosis,	and	management	of	shunt	infection	are	discussed.	Indications	of	prophylactic	antibiotics	for	
patients	with	CSF	shunt	going	for	dental	procedures,	gastrostomy,	and	laparotomy	are	discussed.
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Treatment of Refractory Multiple Sclerosis
Finn Sellebjerg
Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
Treatment	with	interferon-beta	or	glatiramer	acetate	has	been	in	routine	use	for	the	treatment	of	clinically	
isolated	syndromes	and	relapsing-remitting	multiple	sclerosis	(RRMS)	for	almost	two	decades.	Although	
many	patients	 remain	clinically	and	radiologically	stable	on	 treatment,	other	patients	have	either	
radiological	evidence	of	ongoing	disease	activity,	continue	to	have	relapses,	or	develop	a	progressive	
disease	course.	Whether	such	patients	should	be	considered	non-responsive,	ie	refractory	to	treatment,	
or	to	merely	have	an	insufficient	response	remains	a	matter	of	debate.	
	 Some	of	the	emerging	oral	therapies,	eg	dimethylfumarate,	laquinimod	and	teriflunomide	have	been	
compared	to	the	well-known,	injectable	first-line	therapies	in	randomised	controlled	trials	without	clear	
evidence	of	significant	differences	in	clinical	efficacy.	
	 For	patients	with	high	disease	activity	 treatment	 immunosuppression	with	mitoxantrone	or	
cyclophosphamide	has	been	used	in	some	countries,	and	may	still	be	an	option	for	patients	converting	
to	a	secondary	progressive	disease	course,	although	toxicity	limits	the	general	use	of	these	treatments.	
Natalizumab	is	widely	used	as	a	second-line	treatment	for	RRMS,	but	has	never	been	compared	to	other	
treatments	in	phase	3	trials.	Fingolimod	treatment	was	superior	to	interferon-beta	1a	in	one	clinical	trial.	
In	some	countries	fingolimod	is	licensed	as	a	first-line	therapy,	in	other	countries	only	for	patients	with	
high	disease	activity	or	as	a	second-line	therapy.	Most	recently,	lymphocyte	depletion	with	alemtuzumab	
was	shown	to	be	superior	to	interferon	beta-1	both	as	first-line	and	second-line	therapy.	
	 The	choice	of	treatment	for	the	individual	patient	with	an	insufficient	treatment	response	will	depend	
on	a	thorough	evaluation	of	the	previous	disease	course,	treatment	history,	the	presence	of	risk	factors	
for	severe	side-effects	of	therapy,	and	the	evidence	of	efficacy	for	the	treatment	options	considered.	
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The ‘Not So Common’ Causes of Central Nervous System Infection in Hong  
Kong: Diagnoses You Cannot Afford to Miss
Jasper FW Chan
Department of Microbiology, Li Ka Shing Faculty of Medcine, The University of Hong Kong, Hong Kong SAR
Infection	of	the	central	nervous	system	is	an	infectious	disease	emergency	frequently	encountered	by	
the	neurologists	in	clinical	practice.	Early	diagnosis	and	treatment	is	essential	in	reducing	the	significant	
morbidity	and	mortality	associated	with	these	infections.	Unfortunately,	up	to	two	thirds	of	encephalitis	
cases	and	a	 large	number	of	chronic	or	partially	treated	acute	meningitis	cases	remain	of	unknown	
aetiology	despite	an	extensive	diagnostic	workup.	In	a	metropolitan	city	with	a	high	standard	of	health	
care	like	Hong	Kong,	most	physicians	are	competent	in	managing	patients	with	central	nervous	system	
infections	caused	by	common	pathogens	with	established	diagnostic	algorithms	and	treatment	strategies.	
However,	cases	caused	by	unusual	pathogens	or	those	with	atypical	manifestations	often	cause	diagnostic	
dilemmas,	and	hence,	delay	in	treatment.	An	individualised	clinical	management	approach	with	a	specific	
focus	on	epidemiological	risk	assessment	and	close	liaison	with	the	clinical	microbiology	laboratory	for	
state-of-the-art	diagnostic	tests	are	essential	in	deciphering	the	secrets	of	infections	caused	by	these	‘not	
so	common’	bugs.
Ten Minutes Vestibular Examinations but Persistent Rehabilitative Exercises
Dennis KK Au
Department of Surgery, Li Ka Shing Faculty of Medcine, The University of Hong Kong, Hong Kong SAR
Vertigo	 is	a	common	 illness	 that	patients	seek	consultation	 in	ENT	clinics.	Patients	often	have	a	
hallucination	of	environmental	 rotation	while	patients	with	dizziness	often	have	a	sense	of	 light-
headedness.	This	presentation	will	 introduce	some	useful	but	succinct	clinical	examinations	 that	
medical	practitioners	can	do	in	about	10	minutes	to	make	initial	diagnosis	whether	the	vertigo	has	a	
peripheral	or	central	cause	before	referring	the	patient	for	more	sophisticated	vertigo	and	vestibular	
assessments.	Some	latest	technologies	in	assessing	vestibular	functions	are	also	introduced.	Vestibular	
or	dizzy	rehabilitative	exercise	should	follow	if	permanent	vestibular	paresis	is	found.	With	unilateral	
vestibular	lesions,	asymmetry	of	tonic	vestibulospinal	activity	may	lead	to	postural	and	gait	imbalance.	
With	 symmetrical	 vestibular	 loss,	 the	 imbalance	will	be	more	pronounced	and	persistent.	This	
presentation	introduces	some	vestibular	or	dizziness	exercises	that	can	be	practised	by	the	patients	at	
home.	These	exercises	try	to	provoke	imbalance	and	dizziness	but	at	the	same	time	try	to	improve	the	
brain	to	compensate	for	any	abnormalities	in	the	vestibular	system	and	to	retrain	the	brain	to	adapt	and	
tolerate	the	information	from	the	deficit	vestibular	apparatus.	The	exercises	also	train	the	visual	and	
somatosensory	systems	to	compensate	and	assist	in	balancing	and	reduce	the	sense	of	dizziness.	
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Neurostimulation in Primary Headache Disorders
Raymond CK Chan
Department of Medicine, United Christian Hospital, Hong Kong SAR
Primary	headaches	are	common	neurological	problems	and	are	a	socioeconomic	burden.	The	quality	
of	life	can	be	severely	jeopardised	if	the	pain	is	not	adequately	controlled.	The	chronic	forms,	chronic	
daily	headache,	are	the	most	disabling	and	are	usually	refractory	to	medications.	Primary	chronic	daily	
headaches	can	be	due	to	chronic	tension-type	headache	(CTTH),	chronic	migraine	(CM),	new	daily	
persistent	headache	(NDPH),	chronic	cluster	headache	(CCH),	chronic	paroxysmal	hemicrania	(CPH),	
short-lasting	unilateral	neuralgiform	headache	attacks	with	conjunctival	injection	and	tearing	(SUNCT),	
short-lasting	unilateral	neuralgiform	headache	attacks	with	autonomic	symptoms	(SUNA)	and	hemicrania	
continua	(HC).	
	 Neurostimulation	 is	recently	emerging	as	a	novel	 treatment	modality	 for	patients	with	chronic,	
disabling,	 and	drug-refractory	primary	headache	disorders.	Central	neurostimulation	methods	
include	deep-brain	stimulation	(DBS)	and	transcranial	magnetic	stimulation	(TMS)	whereas	peripheral	
neurostimulation	modalities	include	occipital	nerve	stimulation	(ONS),	vagus	nerve	stimulation	(VNS),	
sphenopalatine	ganglion	stimulation	 (SPS),	auriculotemporal	nerve	stimulation	and	supraorbital	
nerve	stimulation.	The	preliminary	results	of	DBS	and	ONS	are	promising.	Currently	there	are	more	
than	60	patients	with	drug-resistant	cluster	headache	(CH)	implanted	with	DBS	with	64%	success	rate	
in	pain	reduction.	The	rationale	of	DBS	in	CH	stems	from	the	finding	of	hyperactivation	of	posterior	
hypothalamus	 in	 the	 functional	 imaging	during	headache	attack.	For	ONS,	 its	efficacy	 in	 treating	
headache	pain	was	first	observed	from	its	successful	treatment	in	drug-resistant	occipital	neuralgia	and	
so	far	there	are	about	500	CM	and	90	CH	patients	treated	by	ONS	with	pain	improvement	rate	of	56%	and	
67%,	respectively.	In	the	ongoing	randomised	controlled	trial,	the	ONSTIM	trial,	the	preliminary	results	
suggest	that	ONS	is	more	effective	than	placebo	or	medical	therapy	in	medically	 intractable	chronic	
migraine.	
	 In	summary,	ONS	and	DBS	of	posterior	hypothalamus	seem	to	be	effective	in	CCH,	and	ONS	seems	
to	be	a	promising	treatment	in	CM.	More	data	from	further	randomised	controlled	trial	are	needed	to	
confirm	their	efficacy.	
Late-onset Pompe Disease in the New Enzyme Replacement Therapy Era
Bun Sheng
Department of Medicine and Geriatrics, Princess Margaret Hospital, Hong Kong SAR
Pompe	disease	(PD)	is	an	autosomal	recessive	disorder	caused	by	the	deficiency	of	lysosomal	enzyme	
acid	α-glucosidase	(GAA).	The	disease	has	two	clinical	forms.	The	classic	infantile	form	develops	severe	
hypotonia	and	hypertrophic	cardiomyopathy	shortly	after	birth.	Until	enzyme	replacement	therapy	
(ERT)	becomes	available,	victims	of	this	devastating	form	seldom	survive	beyond	their	second	birthday.	
Late-onset	PD	(LOPD)	is	more	heterogeneous.	Patients	usually	present	with	a	 limb	girdle	pattern	of	
muscle	weakness	and	develop	respiratory	impairment	early	on,	but	the	heart	is	almost	always	spared.	
The	clinical	form	and	severity	of	the	phenotype	is	correlated	to	the	amount	of	residue	GAA	activity,	
which	is	determined	by	the	mutations.	 In	a	compound	heterozygous	mutation,	 if	one	allele	carries	
a	severe	mutation,	eg	frame	shift,	 the	resulted	phenotype	will	be	a	severe	one.	Unfortunately,	 the	
common	mutation	in	Chinese	is	a	severe	one;	our	LOPD	patients	often	have	severe	phenotype,	with	
earlier	symptom	presentation,	respiratory	failure,	and	requirement	of	assisted	ventilation.	ERT	with	
alglucosidase-α	 (myozyme)	was	first	 licensed	by	Food	and	Drug	Administration	in	2006	for	treatment	
of	infantile	PD,	and	the	drug	was	available	in	Hong	Kong	since	2008.	Following	the	publication	on	the	
first	randomised	trial	of	myozyme	in	LOPD	in	2010,	Hong	Kong	started	the	first	ERT	on	two	brothers	in	
December	2010.	There	are	now	five	LOPD	patients	on	ERT.	Four	patients	had	ERT	for	more	than	1	year,	
all	showed	improvement	or	stabilisation	of	their	respiratory	function	and	mobility,	the	overall	response	
was	comparable	or	even	better	 than	that	 in	the	clinical	 trials.	Nevertheless,	 these	patients	have	an	
aggressive	phenotype;	their	clinical	course	is	different	from	the	subjects	in	clinical	trials.	It	is	still	too	early	
to	conclude	whether	these	early	benefits	could	be	sustainable	over	time.	ERT	not	only	brings	the	first	
effective	treatment	in	LOPD,	it	also	magnifies	the	benefit	of	adjuvant	therapies	including	nutrition	and	
exercise,	which	only	provide	transient	or	short-term	effects	in	the	pre-ERT	era.	New	strategies	to	improve	
the	efficacy	of	ERT	is	on-going;	better	tissue	delivery,	autophagy	targeted,	biologic	chaperones,	and	the	
use	of	β2	agonist	albuterol	to	boost	the	lean	muscle	are	among	the	many	fancy	ideas.	Many	questions	
await	answers	and	many	problems	are	unsettled,	but	a	better	future	is	promised	in	LOPD.	
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Experience of Using Intravenous Thrombolysis in Elderly Patients with Major  
Acute Ischaemic Stroke in Kwong Wah Hospital
Helen Yip, MC Kwan, WK Cheng, WY Lau, KF Ko, TY Chan, ML Lai
Department of Medicine and Geriatrics, Kwong Wah Hospital, Hong Kong SAR
Elderly	patients	with	major	ischaemic	strokes	may	remain	severely	handicapped	or	dead.	We	reported	
two	elderly	patients	aged	greater	than	80	years	at	the	time	of	intravenous	thrombolysis	treatment	given	in	
2009	to	2010.
	 An	84-year-old	man	(patient	1)	with	a	history	of	paroxysmal	atrial	fibrillation	was	admitted	to	Kwong	
Wah	Hospital	in	March	2010	for	congestive	heart	failure.	He	developed	acute	right	hemiplegia	during	
hospitalisation	with	NIHSS	26.	Urgent	computed	tomography	(CT)	of	 the	brain	was	unremarkable.	
Intravenous	thrombolysis	was	commenced	after	evaluation.	Follow-up	NIHSS	1	day	later	was	13.	CT	
following	the	next	day	revealed	an	infarct	in	anterior	part	of	left	middle	cerebral	artery	territory.	There	
was	no	sign	of	haemorrhagic	transformation.	Stroke	risk	factors	were	being	optimised.	He	was	able	to	
walk	with	stick	under	supervision	with	residual	expressive	dysphasia	after	a	course	of	rehabilitation.	
Improvement	of	Barthel	Index	(BI)	from	0	to	79	was	reported	after	3	months	of	training.
	 Another	83-year-old	woman	(patient	2)	was	able	 to	walk	unaided	prior	 to	admission.	She	had	a	
history	of	hypertension	and	was	admitted	in	year	2009	for	hyperacute	stroke	presented	with	dense	right	
hemiplegia	upon	admission	with	NIHSS	15.	Urgent	CT	of	brain	was	unremarkable.	She	was	treated	with	
intravenous	thrombolysis	with	good	neurological	recovery.	The	patient	was	discharged	to	rehabilitative	
care	on	day	8.	At	3-month	follow-up,	she	was	able	to	walk	with	stick	with	good	achievement	in	BI	score	
from	48	to	90	after	rehabilitation.	
	 Acute	thrombolysis	therapy	is	an	effective	treatment	for	acute	ischaemic	stroke.	However,	elderly	
patients	have	mostly	been	excluded	from	acute	revascularisation	trials,	due	to	poor	prognosis	as	a	result	
of	concurrent	medical	illness,	and	fear	of	haemorrhagic	events	from	these	treatment.
	 The	above	two	cases	showed	that	thrombolysis	benefits	elderly	stroke	patients.	Improvement	in	BI	
was	contemplated	in	these	two	patients.	In	carefully	selected	patients	who	meet	eligibility	criteria	for	
thrombolysis,	treatment	should	not	be	withheld	on	the	basis	of	age	alone.	
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Griffiths Mental Developmental Scales Validation for Chinese Children
Winnie WY Tso1, LI Ao2, M Li3, X Zhang4, FY Jiao5, X Xu6, KX Du7, XL Xia8, Denise Challis9, Virginia CN Wong1
1 Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong SAR
2 Rehabilitation Medicine, The Second Affiliated Hospital of Kunming Medical University, PR China 
3 Child Neuro-Habilitation Clinic, Department of Paediatrics, The First Hospital of Peking University, PR China
4 Department of Child and Adolescent Health, Vice-Dean of School of Public Health, Tianjin Medical University, PR China
5 Department of Paediatrics, Shaanxi Provincial People’s Hospital of Xi’an Medical University, PR China
6 Child Health Care Department, The Paediatric Hospital of FuDan University, Shanghai, PR China
7 Department of Child Neurology, The Third Affiliated Hospital of ZhengZhou University, PR China
8 The Second Affiliated Hospital of Kunming Medical University, PR China
9 Research and Re-standardisation Committee, The Association for Research in Infant and Child Development
Background:	The	Griffiths	Mental	Developmental	Scales	(GMDS)	have	been	used	extensively	by	doctors	
and	psychologists	 in	many	countries	to	assess	a	child’s	developmental	profile.	 In	China,	 there	 is	an	
increasing	awareness	of	developmental	disorders	in	children;	the	prevalence	of	preschool	children	with	
developmental	disorders	was	reported	to	be	as	high	as	12.97%.	The	GMDS	have	been	devised	based	on	
observation	of	the	performance	of	children	living	in	the	West.	However,	there	are	obvious	differences	in	
the	culture	and	beliefs	of	people	growing	up	in	Asia	as	compared	to	those	living	in	western	societies.	In	
this	study,	the	GMDS	have	been	translated	into	Chinese	and	modified	according	to	Chinese	culture.	This	
prospective	study	aimed	to	provide	validation	of	the	GMDS	for	Chinese	children.	
Methods:	Chinese	children	from	seven	different	cities	in	China	with	apparently	normal	development	with	
no	significant	medical	history	were	recruited	into	the	study.	Their	developments	were	assessed	using	the	
GMDS.	
Results:	GMDS	scores	were	collected	and	analysed	for	a	total	of	815	Chinese	children	with	ages	ranging	
from	1	month	to	8	years	old;	391	(48%)	were	female.	Smooth	‘developmental	growth’	charts	and	standard	
deviation/percentile	scores	were	computed	for	each	of	the	neurological	developmental	scales	using	the	
LMS	method.	Plots	of	the	1st,	2.5th,	5th,	10th,	25th,	50th,	75th,	90th,	95th,	97.5th,	and	99th	percentiles	will	
be	presented	for	each	of	the	six	sub-scales	and	the	overall	Griffiths	score.	
Conclusion:	There	are	differences	in	the	Chinese	developmental	percentile	curves	as	compared	to	the	
British	developmental	percentile	curves.	These	differences	are	most	obvious	in	subscale	F.	Chinese	
children	should	be	assessed	using	our	validated	Chinese	‘developmental	growth’	charts.	This	will	prevent	
under-estimating	or	over-estimating	the	developmental	milestones	in	Chinese	children.	
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The Prognosis of Acute Symptomatic Seizures after Ischaemic Stroke 
T Leung, H Leung, Y Soo, C Leung, V Mok, KS Wong
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR
Background and purpose:	Seizure	is	an	important	co-morbidity	of	stroke.	This	study	investigated	the	
characteristics/prognosis	of	patients	with	acute	symptomatic	seizure	(AS)	(early,	<7	days	of	stroke)	after	
ischaemic	stroke	(IS).	These	outcome	measures	are	important	when	considering	controversial	treatment	
options	in	patients	with	concurrent	IS/AS.
Methods:	We	prospectively	 investigated	2925	IS	patients	 from	a	population-based	acute	stroke	unit	
(ASU).	The	stroke-related	parameters	were	age/sex,	stroke	aetiology,	stroke	severity,	functional	disability,	
transient-complete	occlusion,	or	partial	 recanalisation,	multiple-territory	 infarct	and	haemorrhagic	
transformation.	The	seizure-related	parameters	were	(1)	AS	co-occurring	with	incident	IS	(CS,	day	2-7	
after	stroke),	(2)	AS	following	the	recurrence	of	IS	(ASS	>7	days	after	incident	stroke	with	another	IS/AS),	
(3)	remote	symptomatic	seizure	(US,	>7	days	after	incident	stroke	without	IS).	We	excluded	patients	with	
intracerebral	haemorrhage,	subdural	haematoma,	subarachnoid	haemorrhage,	or	venous	infarcts.	
Results:	The	incidence	of	AS	in	IS	was	3.9%	(115/2925).	A	total	of	104	patients	with	AS/IS	(mean	age,	65	
years;	55%	female)	had	a	mean	National	Institute	of	Stroke	Scale	(NIHSS)	score	of	11.	Cardio-embolism	
was	found	in	48.1%	(50/104)	and	transient-complete	occlusion/partial	recanalisation	in	30.8%	(32/104).	
Haemorrhagic	transformation	was	only	found	in	16.4%	(17/104).	The	combined	risk	of	CS+ASS	was	28%	at	
1	year,	30%	at	2	years	and	40%	at	8	years.	The	risk	of	developing	US	was	28%	at	8	years.	Status	epilepticus,	
presence	of	another	acute	symptomatic	cause,	>2	cardiovascular	risk	factors	were	predictive	of	CS+ASS	
(P<0.05)	and	epileptiform	discharge	on	electroencephalogram	(EEG)	for	US	(P=0.04).	Subgroup	analysis	of	
AS/IS	with	seizure-at-onset	did	not	differ	in	their	characteristics	or	prognostic	indicators.	
Conclusions:	While	the	long-term	risk	of	developing	epilepsy	after	IS/AS	was	only	28%,	additional	acute	
symptomatic	seizures	are	found	with	 index	stroke	or	during	recurrent	strokes	 in	another	40%.	This	
has	 implications	for	short–to–medium	term	antiepileptic	drug	treatment.	The	prognosis	 in	terms	of	
haemorrhagic	transformation	in	patients	presenting	with	ischaemic	stroke	and	seizure	at	onset	without	
thrombolysis	being	given	was	16%.	
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